Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEYOND Study of zigakibart in adults with IgA nephropathy
2023-503743-34-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Zigakibart with Placebo (2 arms). Primary endpoint: Change from baseline to Week 104 in eGFR. Planned start Jun 2024; status: authorised.
02
Drugs
zigakibart
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2023-503743-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503743-34-00.